Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Pharmacological reports : PR – December 01, 2024
Source: PubMed
Summary
Psilocybin shows remarkable potential in treating depression by triggering a cascade of brain chemistry changes. The compound works by activating 5-HT2A receptors in the brain, which increases glutamate release. This boost in glutamate leads to higher GABA activity, creating a balanced brain state that helps alleviate depressive symptoms and promotes neural adaptability.
Abstract
In recent decades, psilocybin has gained attention as a potential drug for several mental disorders. Clinical and preclinical studies have provided evidence that psilocybin can be used as a fast-acting antidepressant. However, the exact mechanisms of action of psilocybin have not been clearly defined. Data show that psilocybin as an agonist of 5-HT2A receptors located in cortical pyramidal cells exerted a significant effect on glutamate (GLU) extracellular levels in both the frontal cortex and hippocampus. Increased GLU release from pyramidal cells in the prefrontal cortex results in increased activity of γ-aminobutyric acid (GABA)ergic interneurons and, consequently, increased release of the GABA neurotransmitter. It seems that this mechanism appears to promote the antidepressant effects of psilocybin. By interacting with the glutamatergic pathway, psilocybin seems to participate also in the process of neuroplasticity. Therefore, the aim of this mini-review is to discuss the available literature data indicating the impact of psilocybin on glutamatergic neurotransmission and its therapeutic effects in the treatment of depression and other diseases of the nervous system.